LLY

987.92

-1.6%↓

JNJ

227.29

+0.23%↑

ABBV

210.02

-0.19%↓

UNH

385.81

-1.99%↓

AZN

183.55

+1.06%↑

LLY

987.92

-1.6%↓

JNJ

227.29

+0.23%↑

ABBV

210.02

-0.19%↓

UNH

385.81

-1.99%↓

AZN

183.55

+1.06%↑

LLY

987.92

-1.6%↓

JNJ

227.29

+0.23%↑

ABBV

210.02

-0.19%↓

UNH

385.81

-1.99%↓

AZN

183.55

+1.06%↑

LLY

987.92

-1.6%↓

JNJ

227.29

+0.23%↑

ABBV

210.02

-0.19%↓

UNH

385.81

-1.99%↓

AZN

183.55

+1.06%↑

LLY

987.92

-1.6%↓

JNJ

227.29

+0.23%↑

ABBV

210.02

-0.19%↓

UNH

385.81

-1.99%↓

AZN

183.55

+1.06%↑

Home・Akcijų sąrašas・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

49 -0.16

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

48.57

Max

49.86

Pagrindiniai rodikliai
By Trading Economics
Pajamos	36M -2.3M
Pardavimai	-3.9M 208M
P/E Sektoriaus vid.	48.435 51.415
Pelnas, tenkantis vienai akcijai	0.208
Pelno marža	-1.104
Darbuotojai	778
EBITDA	-72M 19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+27.8% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	65M 2.9B
Ankstesnė atidarymo kaina	49.16
Ankstesnė uždarymo kaina	49

Naujienos nuotaikos

By Acuity

58%

42%

256 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

31.35 / 32.36 Palaikymas ir pasipriešinimas

Supernus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-17 23:53; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-17 23:50; UTC

Rinkos pokalbiai

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-17 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

2026-05-17 23:07; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Transactions Part of Group's Capital Reallocation Strategy

2026-05-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Share Sale Agreements Entered With Singland Properties

2026-05-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Divestments' Aggregate Consideration of S$299M in Cash

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Fund Stake Acquisition via Internal Resources

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire Stake for $389 Million

2026-05-17 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

2026-05-16 16:27; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

2026-05-16 15:26; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

2026-05-16 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Supernus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

27.8% į viršų

12 mėnesių prognozė

Vidutinis 63.17 USD 27.8%

Aukščiausias 66 USD

Žemiausias 55 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Supernus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Supernus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

31.35 / 32.36Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

256 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.